Anatomic Pathology Team

Brendan Podell

Dr. Brendan Podell
Assistant Professor, Department of Microbiology, Immunology and Pathology
Office: 316 Pathology
Phone: (970) 491-5746
Email: Brendan.Podell@colostate.edu

Dr. Podell’s laboratory emphasizes research in mechanisms of disease, pathogenesis, and pathology. These areas of study are applied in the development of animal models to better understand host-pathogen interaction, identification of factors influencing host susceptibility to infection, and for the identification of new host-directed treatment approaches. Among animal models of tuberculosis, our laboratory focuses primarily on the guinea pig model, which most accurately reflects the pathology of human patients with active tuberculosis. This model is currently being studied to better understand the mechanisms by which diabetes increases the risk of developing active tuberculosis disease, a comorbidity of emerging importance, especially in countries where tuberculosis is endemic. In conjunction with the laboratory of Dr. Randall Basaraba, we have developed the first guinea pig model of type 2 diabetes and diabetes-tuberculosis comorbidity.

Kelly Hughes

Dr. Kelly Hughes, Dvm, PhD, DACVP
Associate Anatomic Pathologist
Email: Kelly.Hughes@colostate.edu

Dr. Hughes is an anatomic pathologist with expertise in immunologic aspects of canine lymphoproliferative disease. After veterinary school, Dr. Hughes completed an anatomic pathology residency and master’s degree at Oregon State University focused on studying canine mammary cancer and the circadian clock. Following residency training, Dr. Hughes completed a PhD with Dr. Anne Avery at the Clinical Immunology Laboratory at Colorado State University. Through this advanced training, Dr. Hughes has gained experience and expertise in canine and feline flow cytometry and WHO classification of lymphoproliferative disease in these species. Dr. Hughes’ research interests have been primarily focused on characterization of the histomorphology, biology, immunopathology and molecular features of lymphoma/leukemia with the intention of investigating and utilizing these concepts in other types of tumors.